Filana Therapeutics
FLNA
48 hedge funds and large institutions have $20.9M invested in Filana Therapeutics in 2016 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 9 increasing their positions, 11 reducing their positions, and 8 closing their positions.
122% more call options, than puts
Call options by funds: $327K | Put options by funds: $147K
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
2% more funds holding
Funds holding: 47 → 48 (+1)
18% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 11
63% less capital invested
Capital invested by funds: $55.6M → $20.9M (-$34.8M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$886K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$333K |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$304K |
| 4 |
SIM
Spark Investment Management
New York
|
+$283K |
| 5 |
Renaissance Technologies
New York
|
+$261K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$6.21M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$4.41M |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$1.55M |
| 4 |
TA
Teton Advisors
Rye,
New York
|
-$192K |
| 5 |
6CM
683 Capital Management
New York
|
-$178K |
FLNA Hedge Fund Activity: Q3 2016 in Review
48 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q3 2016, worth a combined $20.9M — down 63% from $55.6M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new FLNA positions and 8 closed out — a net gain of 1 holder — while 9 added to existing stakes and 11 trimmed.
The largest buyer was Vanguard Group, adding an estimated $886K. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $6.21M sold.
- 48 institutional investors held Filana Therapeutics (FLNA) as of Q3 2016, up from 47 in Q2 2016.
- Funds reported $20.9M of Filana Therapeutics stock for Q3 2016, down 63% quarter-over-quarter.
- 9 funds opened new Filana Therapeutics positions in Q3 2016 and 8 closed out, a net change of +1 holder.
- The largest Filana Therapeutics buyer in Q3 2016 was Vanguard Group, an estimated $886K added.
- The largest Filana Therapeutics seller in Q3 2016 was Stonepine Capital Management, an estimated $6.21M sold.
Based on aggregated 13F filings for Q3 2016.